OFIX

Over the past six months (approximately April 2026 to October 2026), Orthofix Medical, Inc. (OFIX) stock experienced a decline, with the share price on September 23, 2026, at $9.18, representing a 37.97% decrease from $14.80 on September 24, 2025. The stock's 52-week high was $16.99 and its 52-week low was $8.50. Key events impacting the stock price included the Q1 2026 Earnings Report on May 5, 2026, where the company reported a net loss of $(20.9) million and non-GAAP pro forma adjusted EBITDA of $9.7 million, reaffirming its full-year guidance despite commercial transitions. The Q2 2026 Earnings Report on August 5, 2026, showed progress with net sales of $210.9 million, an increase of 4% reported and 5% pro forma constant currency compared to Q2 2025, leading the company to raise its full-year 2026 guidance for both net sales and adjusted EBITDA, and reporting an adjusted loss of $0.39 per share, beating consensus estimates. Additionally, analyst rating changes occurred, with Canaccord Genuity Group reducing its target price to $13.00 while maintaining a 'buy' rating, Barrington Research lifting its target to $17.00 with an 'outperform' rating, Stifel lowering its target to $13.00, and Weiss Ratings downgrading Orthofix Medical from a 'sell (d-)' to a 'sell (e+)' rating.